Various genetic polymorphisms have been reported to be associated with antipsychotic-induced weight gain. In this study, we aimed to determine whether risk polymorphisms in 12 candidate genes are associated with reduction in body mass index (BMI) of patients following switching of antipsychotics to aripiprazole or ziprasidone.


We recruited 115 schizophrenia patients with metabolic abnormalities and who have been on at least 1 year treatment with otherantipsychotics; they were then switched to either aripiprazole or ziprasidone. They were genotyped, and their BMI monitored for 6 months.


Significant associations with reduction in BMI at 6 months following switching were found in two of these genes: with rs1800544 of the ADRA2A gene (CC + CG [0.32 ± 1.41 kg/m2] vs GG [1.04 ± 1.63 kg/m2], p= 0.013) and with rs1801131 of the MTHFR gene (AA[0.36 ± 1.53] vs AC + CC [1.07 ± 1.53], p= 0.015).


The study data indicated that carriage of the ADRA2A rs1800544 GG genotype and the MTHFR rs1801131 C allele are associated with BMI reduction in this population following switching of antipsychotics to aripiprazole and iprasidone.

Read More Here